Cemiplimab

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, according to the agent’s manufacturer.

Cemiplimab provided clinically meaningful responses for patients with metastatic and locally advanced cutaneous squamous cell carcinoma, according to a study.

An immunotherapy combination improved outcomes compared with historical control for certain patients with advanced melanoma, according to a topline data announcement.

Prior radiotherapy was associated with progression-free survival in patients with metastatic cutaneous squamous cell carcinoma treated with cemiplimab, according to a study.

In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more.

MADRID — A treatment regimen of cemiplimab plus chemotherapy showed improvement over chemotherapy alone, according to research presented at ESMO Congress.

The addition of cemiplimab to chemotherapy significantly improved pain symptoms and delayed time to definitive clinically meaningful deterioration of disease symptoms and functions among patients with advanced non-small cell lung cancer.

Neoadjuvant cemiplimab induced a pathologic complete response among a majority of patients with resectable cutaneous squamous cell carcinoma, according to results of a nonrandomized phase 2 study presented at ESMO Congress.

Cemiplimab extended OS compared with single-agent chemotherapy for women with recurrent cervical cancer, according to randomized phase 3 study results published in The New England Journal of Medicine.

More than one-third of a small cohort patients with early-stage hepatocellular carcinoma achieved at least 50% tumor necrosis following neoadjuvant treatment with cemiplimab, results of a phase 2a trial showed.